Market closedNon-fractional

Replimune/REPL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Replimune

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Ticker

REPL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Woburn, United States

Employees

331

Replimune Metrics

BasicAdvanced
$497M
Market cap
-
P/E ratio
-$3.24
EPS
1.26
Beta
-
Dividend rate
$497M
1.26
10.724
10.525
19.223
20.258
-34.96%
-25.66%
-46.42%
1.34
1.34
-2.818
8.27%
22.85%

What the Analysts think about Replimune

Analyst Ratings

Majority rating from 9 analysts.
Buy

Replimune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$0
NaN%
Net income
-$55M
7.63%
Profit margin
0.00%
NaN%

Replimune Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.47%
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.75
-$0.90
-$0.77
-$0.82
-
Expected
-$0.84
-$0.86
-$0.93
-$0.79
-$0.87
Surprise
-11.14%
5.18%
-16.99%
3.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Replimune stock?

Replimune (REPL) has a market cap of $497M as of July 05, 2024.

What is the P/E ratio for Replimune stock?

The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of July 05, 2024.

Does Replimune stock pay dividends?

No, Replimune (REPL) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Replimune dividend payment date?

Replimune (REPL) stock does not pay dividends to its shareholders.

What is the beta indicator for Replimune?

Replimune (REPL) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Replimune stock

Buy or sell Replimune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing